Lucas M. M. R.
- Country
- Spain
- Department
- Oncology for pediatrics
Research Overview
- Phase 2/3 Study of hu14.18K322A Combined with Irinotecan and Temozolomide in Children with Relapsed or Refractory High‑Risk Neuroblastoma
- Safety and Feasibility of AloCelyvir Combined with Autologous IL‑7/15/21‑Expanded TILs in Children/Young Adults with High‑Risk Relapsed/Refractory Neuroblastoma
- Phase I/II Evaluation of Sodium 2-Hydroxylinoleate in Pediatric Relapsed/Refractory Neuroblastoma and Solid Tumors, Alone and with Chemotherapy or Targeted Therapies
Data & Insights
Has run more than one trial at 34 of 75 partner sites.
Specializations
Pediatric Oncology
Investigator leads studies in pediatric oncology targeting malignancies that arise in children and adolescents.
- Acute lymphoblastic leukemia
- Neuroblastoma
- Low‑grade glioma with IDH mutation
- Medulloblastoma
- Rhabdomyosarcoma
Research emphasizes age‑adapted therapeutic strategies and biomarker‑driven approaches.
Hematologic Malignancies
Focus on hematologic malignancies across age groups, exploring novel agents for blood cancers.
- Acute myeloid leukemia
- Myelodysplastic syndrome
- Chronic lymphocytic leukemia
- Diffuse large B‑cell lymphoma
- Multiple myeloma
Efforts include targeting genetic alterations and overcoming treatment resistance.
Targeted Solid Tumor Therapies
Investigator engages in precision oncology for solid tumors with actionable molecular drivers.
- Estrogen receptor‑positive HER2‑negative breast cancer
- Non‑small cell lung cancer with EGFR or KRAS mutations
- Renal cell carcinoma
- Colorectal cancer with microsatellite instability
- Cholangiocarcinoma
Clinical work integrates targeted inhibitors and immunotherapies to improve outcomes.
Immune‑Mediated and Autoimmune Disorders
Research extends to immune‑mediated diseases where dysregulated immunity drives pathology.
- Systemic lupus erythematosus
- Myasthenia gravis
- Vasculitis
- Rheumatoid arthritis
- Inflammatory bowel disease
Studies aim to modulate immune pathways and assess novel biologic agents.
Rare Genetic and Metabolic Disorders
Investigator contributes to therapeutic development for rare genetic disorders with metabolic or oncogenic relevance.
- IDH‑mutant glioma
- Hereditary angioedema
- Alpha‑1 antitrypsin deficiency‑related liver disease
- Gaucher disease
- Fabry disease
Efforts focus on genotype‑specific interventions and disease‑modifying strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.